The role of GPCRs in bone diseases and dysfunctions

Abstract

The superfamily of G protein-coupled receptors (GPCRs) contains immense structural and functional diversity and mediates a myriad of biological processes upon activation by various extracellular signals. Critical roles of GPCRs have been established in bone development, remodeling, and disease. Multiple human GPCR mutations impair bone development or metabolism, resulting in osteopathologies. Here we summarize the disease phenotypes and dysfunctions caused by GPCR gene mutations in humans as well as by deletion in animals. To date, 92 receptors (5 glutamate family, 67 rhodopsin family, 5 adhesion, 4 frizzled/taste2 family, 5 secretin family, and 6 other 7TM receptors) have been associated with bone diseases and dysfunctions (36 in humans and 72 in animals). By analyzing data from these 92 GPCRs, we found that mutation or deletion of different individual GPCRs could induce similar bone diseases or dysfunctions, and the same individual GPCR mutation or deletion could induce different bone diseases or dysfunctions in different populations or animal models. Data from human diseases or dysfunctions identified 19 genes whose mutation was associated with human BMD: 9 genes each for human height and osteoporosis; 4 genes each for human osteoarthritis (OA) and fracture risk; and 2 genes each for adolescent idiopathic scoliosis (AIS), periodontitis, osteosarcoma growth, and tooth development. Reports from gene knockout animals found 40 GPCRs whose deficiency reduced bone mass, while deficiency of 22 GPCRs increased bone mass and BMD; deficiency of 8 GPCRs reduced body length, while 5 mice had reduced femur size upon GPCR deletion. Furthermore, deficiency in 6 GPCRs induced osteoporosis; 4 induced osteoarthritis; 3 delayed fracture healing; 3 reduced arthritis severity; and reduced bone strength, increased bone strength, and increased cortical thickness were each observed in 2 GPCR-deficiency models. The ever-expanding number of GPCR mutation-associated diseases warrants accelerated molecular analysis, population studies, and investigation of phenotype correlation with SNPs to elucidate GPCR function in human diseases.

References

[1] Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science, 2000, 289:1501-1504

[2] Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev., 2002, 16:1446-1465

[3] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423:337-342

[4] Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat. Rev. Genet., 2003, 4:638-649

[5] Huang W, Yang S, Shao J, Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front. Biosci., 2007, 12:3068-3092

[6] Keinan D et al. Role of regulator of G protein signaling proteins in bone. Front Biosci. (Landmark Ed.), 2014, 19:634-648

[7] Jimi E et al. The current and future therapies of bone regeneration to repair bone defects. Int. J. Dent., 2012, 2012:148261

[8] Luo J et al. Regulation of bone formation and remodeling by G-protein-coupled receptor 48. Development, 2009, 136:2747-2756

[9] Luo J et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med., 2016, 22:539-546

[10] Jastrzebska B et al. A G protein-coupled receptor dimerization interface in human cone opsins. Biochemistry, 2017, 56:61-72

[11] Adler E et al. A novel family of mammalian taste receptors. Cell, 2000, 100:693-702

[12] Katidou M, Grosmaitre X, Lin JW, Mombaerts P. G-protein coupled receptors Mc4r and Drd1a can serve as surrogate odorant receptors in mouse olfactory sensory neurons. Mol. Cell. Neurosci., 2018, 88:138-147

[13] Grammatopoulos DK. Regulation of G-protein coupled receptor signalling underpinning neurobiology of mood disorders and depression. Mol. Cell. Endocrinol., 2017, 449:82-89

[14] Sharma N, Akhade AS, Qadri A. Sphingosine-1-phosphate suppresses TLR-induced CXCL8 secretion from human T cells. J. Leukoc. Biol., 2013, 93:521-528

[15] Poole, D. P. & Bunnett, N. W. G protein-coupled receptor trafficking and signalling in the enteric nervous system: the past, present and future. Adv. Exp. Med. Biol. 891, 145–152 (2016).

[16] Hazell GGJ et al. G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei - serpentine gateways to neuroendocrine homeostasis. Front. Neuroendocr., 2012, 33:45-66

[17] Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat. Rev. Cancer, 2007, 7:79-94

[18] Santos R et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov., 2017, 16:19-34

[19] Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov., 2017, 16:829-842

[20] Di Nisio A et al. Calcium-sensing receptor polymorphisms increase the risk of osteoporosis in ageing males. Endocrine, 2018, 61:349-352

[21] Karsak M et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Genet., 2005, 14:3389-3396

[22] Miyake H et al. Allelic variations of the D2 dopamine receptor gene in children with idiopathic short stature. J. Hum. Genet., 1999, 44:26-29

[23] Yamaura K, Oda M, Suzuki M, Ueno K. Lower expression of histamine H(4) receptor in synovial tissues from patients with rheumatoid arthritis compared to those with osteoarthritis. Rheumatol. Int., 2012, 32:3309-3313

[24] Morocz M et al. Association study of BMP4, IL6, Leptin, MMP3, and MTNR1B gene promoter polymorphisms and adolescent idiopathic scoliosis. Spine (Phila Pa 1976), 2011, 36:E123-E130

[25] Iyer SV et al. Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-kappaB and osteosarcoma progression. Nat. Commun., 2016, 7

[26] Mototani H et al. A functional SNP in EDG2 increases susceptibility to knee osteoarthritis in Japanese. Hum. Mol. Genet., 2008, 17:1790-1797

[27] Pantel J et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest., 2006, 116:760-768

[28] Lin L et al. A homozygous R262Q mutation in the gonadotropin-releasing hormone receptor presenting as constitutional delay of growth and puberty with subsequent borderline oligospermia. J. Clin. Endocr. Metab., 2006, 91:5117-5121

[29] Lu S et al. Bivariate genome-wide association analyses identified genetic pleiotropic effects for bone mineral density and alcohol drinking in Caucasians. J. Bone Miner. Metab., 2017, 35:649-658

[30] Ho C et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet., 1995, 11:389-394

[31] Ofek O et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl Acad. Sci. USA, 2006, 103:696-701

[32] Gennero I et al. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone, 2011, 49:395-403

[33] Lips KS et al. Altered ultrastructure, density and cathepsin K expression in bone of female muscarinic acetylcholine receptor M3 knockout mice. Int. Immunopharmacol., 2015, 29:201-207

[34] Kauschke V, Lips KS, Heiss C, Schnettler R. Expression of muscarinic acetylcholine receptors M3 and M5 in osteoporosis. Med. Sci. Monit., 2014, 20:869-874

[35] Tamma R et al. Oxytocin is an anabolic bone hormone. Proc. Natl Acad. Sci. USA, 2009, 106:7149-7154

[36] Bischoff DS et al. CXC receptor knockout mice: characterization of skeletal features and membranous bone healing in the adult mouse. Bone, 2011, 48:267-274

[37] Abe E et al. TSH is a negative regulator of skeletal remodeling. Cell, 2003, 115:151-162

[38] Cho ES, Lim SS, Hwang JW, Lee JC. Constitutive activation of smoothened leads to impaired developments of postnatal bone in mice. Mol. Cells, 2012, 34:399-405

[39] Lanske B et al. Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J. Clin. Invest., 1999, 104:399-407

[40] Mieczkowska A, Irwin N, Flatt PR, Chappard D, Mabilleau G. Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone, 2013, 56:337-342

[41] Ford J et al. GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. J. Bone Miner. Res., 2011, 26:298-307

[42] Hikiji H, Ishii S, Shindou H, Takato T, Shimizu T. Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy. J. Clin. Invest., 2004, 114:85-93

[43] Wauquier F et al. The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J. Biol. Chem., 2013, 288:6542-6551

[44] Attwood TK, Findlay JB. Fingerprinting G-protein-coupled receptors. Protein Eng., 1994, 7:195-203

[45] Kolakowski LF Jr. GCRDb: a G-protein-coupled receptor database. Recept. Channels, 1994, 2:1-7

[46] Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63:1256-1272

[47] Schioth HB, Fredriksson R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen. Comp. Endocrinol., 2005, 142:94-101

[48] Lefkowitz RJ. The superfamily of heptahelical receptors. Nat. Cell Biol., 2000, 2:E133-E136

[49] Kobilka BK. G protein coupled receptor structure and activation. Biochim. Biophys. Acta, 2007, 1768:794-807

[50] Oldham WM, Hamm HE. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol, 2008, 9:60-71

[51] Hurowitz EH et al. Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res., 2000, 7:111-120

[52] McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS. G-protein signaling: back to the future. Cell. Mol. Life Sci., 2005, 62:551-577

[53] Milligan G, Rees S. Chimaeric G alpha proteins: their potential use in drug discovery. Trends Pharmacol. Sci., 1999, 20:118-124

[54] Riddle EL, Schwartzman RA, Bond M, Insel PA. Multi-tasking RGS proteins in the heart: the next therapeutic target? Circ. Res., 2005, 96:401-411

[55] Wieland T, Lutz S, Chidiac P. Regulators of G protein signalling: a spotlight on emerging functions in the cardiovascular system. Curr. Opin. Pharmacol., 2007, 7:201-207

[56] Homan KT, Tesmer JJ. Structural insights into G protein-coupled receptor kinase function. Curr. Opin. Cell Biol., 2014, 27:25-31

[57] He Y et al. Molecular assembly of rhodopsin with G protein-coupled receptor kinases. Cell Res., 2017, 27:728-747

[58] Jean-Charles PY, Kaur S, Shenoy SKG. Protein-coupled receptor signaling through beta-arrestin-dependent mechanisms. J. Cardiovasc. Pharmacol., 2017, 70:142-158

[59] Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu. Rev. Biochem., 1998, 67:653-692

[60] Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol., 2007, 69:511-534

[61] Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science, 2005, 308:512-517

[62] Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking by GRKs and arrestins. Annu. Rev. Physiol., 2007, 69:451-482

[63] Kohout TA, Lin FS, Perry SJ, Conner DA, Lefkowitz RJ. beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc. Natl Acad. Sci. USA, 2001, 98:1601-1606

[64] DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. beta-arrestins and cell signaling. Annu. Rev. Physiol., 2007, 69:483-510

[65] Srivastava A, Gupta B, Gupta C, Shukla AK. Emerging functional divergence of beta-arrestin isoforms in GPCR function. Trends Endocrinol. Metab., 2015, 26:628-642

[66] Gurevich VV, Gurevich EV. Structural determinants of arrestin functions. Prog. Mol. Biol. Transl. Sci., 2013, 118:57-92

[67] Leach K, Conigrave AD, Sexton PM, Christopoulos A. Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias. Trends Pharmacol. Sci., 2015, 36:215-225

[68] Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov., 2013, 12:205-216

[69] Dasgupta C, Zhang L. Angiotensin II receptors and drug discovery in cardiovascular disease. Drug Discov. Today, 2011, 16:22-34

[70] Ferrario CM, Mullick AE. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharm. Res., 2017, 125 Pt A 57-71

[71] Takezako T, Unal H, Karnik SS, Node K. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism. Pharmacol. Res., 2017, 123:40-50

[72] Ikeda Y, Kumagai H, Motozawa Y, Suzuki J, Komuro I. Biased agonism of the angiotensin II type I receptor. Int. Heart J., 2015, 56:485-488

[73] Wu M, Deng L, Zhu G, Li YP. G Protein and its signaling pathway in bone development and disease. Front. Biosci. (Landmark Ed.), 2010, 15:957-985

[74] Jules J, Yang S, Chen W, Li YP. Role of regulators of G protein signaling proteins in bone physiology and pathophysiology. Prog. Mol. Biol. Transl. Sci., 2015, 133:47-75

[75] Hsiao EC, Millard SM, Nissenson RA. Gs/Gi regulation of bone cell differentiation: review and insights from engineered receptors. Horm. Metab. Res., 2016, 48:689-699

[76] Diepenhorst N et al. G protein-coupled receptors as anabolic drug targets in osteoporosis. Pharm. Ther., 2018, 184:1-12

[77] Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev., 2000, 21:90-113

[78] Bowler WB, Gallagher JA, Bilbe G. G-protein coupled receptors in bone. Front. Biosci., 1998, 3:d769-d780

[79] Conklin BR et al. Engineering GPCR signaling pathways with RASSLs. Nat. Methods, 2008, 5:673-678

[80] Kronenberg HM. Gs signaling in osteoblasts and hematopoietic stem cells. Ann. NY Acad. Sci., 2010, 1192:327-329

[81] Saggio I et al. Constitutive expression of Gsalpha(R201C) in mice produces a heritable, direct replica of human fibrous dysplasia bone pathology and demonstrates its natural history. J. Bone Min. Res., 2014, 29:2357-2368

[82] Remoli C et al. Osteoblast-specific expression of the fibrous dysplasia (FD)-causing mutation Gsalpha(R201C) produces a high bone mass phenotype but does not reproduce FD in the mouse. J. Bone Min. Res., 2015, 30:1030-1043

[83] Bliziotes M, Murtagh J, Wiren K. Beta-adrenergic receptor kinase-like activity and beta-arrestin are expressed in osteoblastic cells. J. Bone Miner. Res., 1996, 11:820-826

[84] Spurney RF. Regulated expression of G protein-coupled receptor kinases (GRK’s) and beta-arrestins in osteoblasts. Calcif. Tissue Int., 2003, 73:153-160

[85] Ferrari SL et al. Bone response to intermittent parathyroid hormone is altered in mice null for beta-arrestin2. Endocrinology, 2005, 146:1854-1862

[86] Nevius E et al. Oxysterols and EBI2 promote osteoclast precursor migration to bone surfaces and regulate bone mass homeostasis. J. Exp. Med., 2015, 212:1931-1946

[87] Masuhara M et al. A relation between osteoclastogenesis inhibition and membrane-type estrogen receptor GPR30. Biochem. Biophys. Rep., 2016, 8:389-394

[88] Chang, W. H., Tu, C., Chen, T. H., Bikle, D. & Shoback, D. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci. Signal. 1, ra1 (2008).

[89] James CG, Appleton CT, Ulici V, Underhill TM, Beier F. Microarray analyses of gene expression during chondrocyte differentiation identifies novel regulators of hypertrophy. Mol. Biol. Cell, 2005, 16:5316-5333

[90] Chagin AS, Kronenberg HM. Role of G-proteins in the differentiation of epiphyseal chondrocytes. J. Mol. Endocrinol., 2014, 53:R39-R45

[91] Chagin, A. S. et al. G-protein stimulatory subunit alpha and Gq/11 alpha G-proteins are both required to maintain quiescent stem-like chondrocytes. Nat. Commun. 5, 3673 (2014).

[92] Sakamoto A, Chen M, Kobayashi T, Kronenberg HM, Weinstein LS. Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation. J. Bone Miner. Res., 2005, 20:663-671

[93] Brassai A, Suvanjeiev RG, Ban EG, Lakatos M. Role of synaptic and nonsynaptic glutamate receptors in ischaemia induced neurotoxicity. Brain Res. Bull., 2015, 112:1-6

[94] Hamza TH et al. Glutamate receptor gene GRIN2A, coffee, and Parkinson disease. PLoS Genet., 2014, 10

[95] Wu J, Tang T, Bezprozvanny I. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington’s disease. Neurosci. Lett., 2006, 407:219-223

[96] Akins PT, Atkinson RP. Glutamate AMPA receptor antagonist treatment for ischaemic stroke. Curr. Med. Res. Opin., 2002, 18 Suppl. 2 s9-s13

[97] Elia J et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat. Genet., 2011, 44:78-84

[98] Vadasz C et al. Glutamate receptor metabotropic 7 is cis-regulated in the mouse brain and modulates alcohol drinking. Genomics, 2007, 90:690-702

[99] Schmeisser MJ et al. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature, 2012, 486:256

[100] Skerry TM, Taylor AF. Glutamate signalling in bone. Curr. Pharm. Des., 2001, 7:737-750

[101] Aramori I, Nakanishi S. Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron, 1992, 8:757-765

[102] Rosenmund C, Stern-Bach Y, Stevens CF. The tetrameric structure of a glutamate receptor channel. Science, 1998, 280:1596-1599

[103] Szczesniak AM, Gilbert RW, Mukhida M, Anderson GI. Mechanical loading modulates glutamate receptor subunit expression in bone. Bone, 2005, 37:63-73

[104] Chenu C, Serre CM, Raynal C, Burt-Pichat B, Delmas PD. Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone, 1998, 22:295-299

[105] Patton AJ, Genever PG, Birch MA, Suva LJ, Skerry TM. Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. Bone, 1998, 22:645-649

[106] Gilbert RW, Szczesniak AM, Langman MF, Anderson GI. Variation in expression of glutamate receptor subunits in skeletal tissue with mechanical loading. J. Bone Miner. Res., 1999, 14:S489-S489

[107] Santa Maria C et al. Interplay between CaSR and PTH1R signaling in skeletal development and osteoanabolism. Semin. Cell. Dev. Biol., 2016, 49:11-23

[108] Civitelli R, Ziambaras K. Calcium and phosphate homeostasis: concerted interplay of new regulators. J. Endocrinol. Invest., 2011, 34 7 Suppl. 3-7

[109] Peacock M. Calcium metabolism in health and disease. Clin. J. Am. Soc. Nephrol., 2010, 5 Suppl. 1 S23-S30

[110] Lorentzon M, Lorentzon R, Lerner UH, Nordstrom P. Calcium sensing receptor gene polymorphism, circulating calcium concentrations and bone mineral density in healthy adolescent girls. Eur. J. Endocrinol., 2001, 144:257-261

[111] Takahata Y et al. Osteoblastic gamma-aminobutyric acid, type B receptors negatively regulate osteoblastogenesis toward disturbance of osteoclastogenesis mediated by receptor activator of nuclear factor kappaB ligand in mouse bone. J. Biol. Chem., 2011, 286:32906-32917

[112] Pi M et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS ONE, 2008, 3

[113] Pi M et al. Impaired osteoblast function in GPRC6A null mice. J. Bone Miner. Res., 2010, 25:1092-1102

[114] Musante I et al. Phenotypic characterization of Grm1(crv4) mice reveals a functional role for the type 1 metabotropic glutamate receptor in bone mineralization. Bone, 2017, 94:114-123

[115] Eaton MS et al. Loss of the nutrient sensor TAS1R3 leads to reduced bone resorption. J. Physiol. Biochem., 2018, 74:3-8

[116] Simon BR et al. Sweet taste receptor deficient mice have decreased adiposity and increased bone mass. PLoS ONE, 2014, 9:1

[117] Baldwin JM. Structure and function of receptors coupled to G proteins. Curr. Opin. Cell Biol., 1994, 6:180-190

[118] Lee HJ et al. Association between polymorphisms in leptin, leptin receptor, and beta-adrenergic receptor genes and bone mineral density in postmenopausal Korean women. Menopause, 2014, 21:67-73

[119] Woo JH, Kim H, Kim JH, Kim JG. Cannabinoid receptor gene polymorphisms and bone mineral density in Korean postmenopausal women. Menopause, 2015, 22:512-519

[120] Yamada Y, Ando F, Shimokata H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int. J. Mol. Med., 2007, 19:791-801

[121] Yamada Y, Ando F, Niino N, Shimokata H. Association of a polymorphism of the dopamine receptor D4 gene with bone mineral density in Japanese men. J. Hum. Genet., 2003, 48:629-633

[122] Shi Y et al. Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell. Metab., 2010, 11:231-238

[123] Farooqi IS et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest., 2000, 106:271-279

[124] Garg G et al. Variation in the MC4R gene is associated with bone phenotypes in elderly Swedish women. PLoS ONE, 2014, 9

[125] Mosialou I et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature, 2017, 543:385-390

[126] MacKenzie RG. Obesity-associated mutations in the human melanocortin-4 receptor gene. Peptides, 2006, 27:395-403

[127] Li Y et al. Association of osteoporosis with genetic variants of circadian genes in Chinese geriatrics. Osteoporos. Int., 2016, 27:1485-1492

[128] Mitchell EJ, Canter J, Norris P, Jenkins J, Morris J. The genetics of heterotopic ossification: insight into the bone remodeling pathway. J. Orthop. Trauma, 2010, 24:530-533

[129] He W, Cronstein B. The roles of adenosine and adenosine receptors in bone remodeling. Front. Biosci. (Elite Ed.), 2011, 3:888-895

[130] Kara FM et al. Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. FASEB J., 2010, 24:2325-2333

[131] Kara FM et al. Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Arthritis Rheum., 2010, 62:534-541

[132] Tam J et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol. Pharmacol., 2006, 70:786-792

[133] Idris AI et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med., 2005, 11:774-779

[134] Khalid AB, Goodyear SR, Ross RA, Aspden RM. Mechanical and material properties of cortical and trabecular bone from cannabinoid receptor-1-null (Cnr1(-/-)) mice. Med. Eng. Phys., 2016, 38:1044-1054

[135] Zhang M et al. Loss of the PGE2 receptor EP1 enhances bone acquisition, which protects against age and ovariectomy-induced impairments in bone strength. Bone, 2015, 72:92-100

[136] Lorenz J et al. Melanocortin 1 receptor-signaling deficiency results in an articular cartilage phenotype and accelerates pathogenesis of surgically induced murine osteoarthritis. PLoS ONE, 2014, 9

[137] Ahn JD et al. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology, 2006, 147:3196-3202

[138] Braun TP et al. Regulation of lean mass, bone mass, and exercise tolerance by the central melanocortin system. PLoS ONE, 2012, 7

[139] Mediero A, Kara FM, Wilder T, Cronstein BN. Adenosine A(2A) receptor ligation inhibits osteoclast formation. Am. J. Pathol., 2012, 180:775-786

[140] Mediero A, Wilder T, Perez-Aso M, Cronstein BN. Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2. FASEB J., 2015, 29:1577-1590

[141] Corciulo C, Wilder T, Cronstein BN. Adenosine A2B receptors play an important role in bone homeostasis. Purinergic Signal., 2016, 12:537-547

[142] Carroll SH et al. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J. Biol. Chem., 2012, 287:15718-15727

[143] Pierroz DD et al. Deletion of beta-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation. J. Bone Miner. Res., 2012, 27:1252-1262

[144] Bonnet N, Pierroz DD, Ferrari SL. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. J. Musculoskelet. Neuron. Interact., 2008, 8:94-104

[145] Kumar KK, Tung S, Iqbal J. Bone loss in anorexia nervosa: leptin, serotonin, and the sympathetic nervous system. Ann. NY Acad. Sci., 2010, 1211:51-65

[146] Yadav VK et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell, 2009, 138:976-989

[147] Collet C et al. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J., 2008, 22:418-427

[148] David M et al. Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J. Biol. Chem., 2014, 289:6551-6564

[149] Ahn JD, Dubern B, Lubrano-Berthelier C, Clement K, Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology, 2006, 147:3196-3202

[150] Bohm M, Grassel S. Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research. Endocr. Rev., 2012, 33:623-651

[151] Wasserman E et al. CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Delta9-tetrahydrocannabinol. Ann. NY Acad. Sci., 2015, 1335:110-119

[152] Kim KW et al. Histamine and histamine H4 receptor promotes osteoclastogenesis in rheumatoid arthritis. Sci. Rep., 2017, 7

[153] Zhang M et al. EP1(–/–) mice have enhanced osteoblast differentiation and accelerated fracture repair. J. Bone Miner. Res., 2011, 26:792-802

[154] Akhter MP, Cullen DM, Gong G, Recker RR. Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone, 2001, 29:121-125

[155] Miyaura C et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J. Biol. Chem., 2000, 275:19819-19823

[156] Sakuma Y et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res., 2000, 15:218-227

[157] Sophocleous A, Marino S, Kabir D, Ralston SH, Idris AI. Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition. Aging Cell, 2017, 16:1051-1061

[158] Idris AI, Sophocleous A, Landao-Bassonga E, van’t Hof RJ, Ralston SH. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology, 2008, 149:5619-5626

[159] Sophocleous A, Landao-Bassonga E, Van’t Hof RJ, Idris AI, Ralston SH. The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology, 2011, 152:2141-2149

[160] Sophocleous A, Idris AI, Ralston SH. Genetic background modifies the effects of type 2 cannabinoid receptor deficiency on bone mass and bone turnover. Calcif. Tissue Int., 2014, 94:259-268

[161] Delhanty PJ et al. Genetic manipulation of the ghrelin signaling system in male mice reveals bone compartment specificity of acylated and unacylated ghrelin in the regulation of bone remodeling. Endocrinology, 2014, 155:4287-4295

[162] Ma C et al. Genetic determination of the cellular basis of the ghrelin-dependent bone remodeling. Mol. Metab., 2015, 4:175-185

[163] Shaffer JR et al. GWAS of dental caries patterns in the permanent dentition. J. Dent. Res., 2013, 92:38-44

[164] Tamma R et al. Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc. Natl Acad. Sci. USA, 2013, 110:18644-18649

[165] Lee NJ et al. Osteoblast specific Y1 receptor deletion enhances bone mass. Bone, 2011, 48:461-467

[166] Baldock PA et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J. Biol. Chem., 2007, 282:19092-19102

[167] Baldock PA et al. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest., 2002, 109:915-921

[168] Baldock PA et al. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J. Bone Miner. Res., 2006, 21:1600-1607

[169] Shi YC et al. NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS ONE, 2010, 5

[170] Allison SJ, Baldock PA, Herzog H. The control of bone remodeling by neuropeptide Y receptors. Peptides, 2007, 28:320-325

[171] Sainsbury A et al. Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol. Cell. Biol., 2003, 23:5225-5233

[172] Allison SJ et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J. Biol. Chem., 2006, 281:23436-23444

[173] Lundberg P et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J. Biol. Chem., 2007, 282:19082-19091

[174] Haffner-Luntzer M et al. Hypochlorhydria-induced calcium malabsorption does not affect fracture healing but increases post-traumatic bone loss in the intact skeleton. J. Orthop. Res., 2016, 34:1914-1921

[175] Schinke T et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat. Med., 2009, 15:674-681

[176] Khor EC et al. They6 receptor suppresses bone resorption and stimulates bone formation in mice via a suprachiasmatic nucleus relay. Bone, 2016, 84:139-147

[177] Ruest LB, Kedzierski R, Yanagisawa M, Clouthier DE. Deletion of the endothelin-A receptor gene within the developing mandible. Cell Tissue Res., 2005, 319:447-453

[178] Ruest LB, Clouthier DE. Elucidating timing and function of endothelin-A receptor signaling during craniofacial development using neural crest cell-specific gene deletion and receptor antagonism. Dev. Biol., 2009, 328:94-108

[179] Sato T et al. An endothelin-1 switch specifies maxillomandibular identity. Proc. Natl Acad. Sci. USA, 2008, 105:18806-18811

[180] Tavares AL et al. Ectodermal-derived Endothelin1 is required for patterning the distal and intermediate domains of the mouse mandibular arch. Dev. Biol., 2012, 371:47-56

[181] Clouthier DE, Garcia E, Schilling TF. Regulation of facial morphogenesis by endothelin signaling: insights from mice and fish. Am. J. Med. Genet. A, 2010, 152A:2962-2973

[182] Sousa DM et al. Neuropeptide Y modulates fracture healing through Y1 receptor signaling. J. Orthop. Res., 2013, 31:1570-1578

[183] Ahn SH et al. Free fatty acid receptor 4 (GPR120) stimulates bone formation and suppresses bone resorption in the presence of elevated n-3 fatty acid levels. Endocrinology, 2016, 157:2621-2635

[184] Kim HJ et al. G protein-coupled receptor 120 signaling negatively regulates osteoclast differentiation, survival, and function. J. Cell. Physiol., 2016, 231:844-851

[185] Eraltan H et al. MCP-1 and CCR2 gene variants and the risk for osteoporosis and osteopenia. Genet. Test. Mol. Biomark., 2012, 16:229-233

[186] Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS, 2004, 18:729-738

[187] Cho YA, Kim J. Association of polymorphisms in the MCP-1 and CCR2 genes with the risk of cancer: a meta-analysis. Cytokine, 2013, 64:213-220

[188] Huang Y et al. Relationship between CCR2-V64I polymorphism and cancer risk: a meta-analysis. Gene, 2013, 524:54-58

[189] Hoshino A et al. Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts. J. Cell Sci., 2013, 126:1032-1045

[190] Goncalves-Zillo TO et al. Increased bone loss and amount of osteoclasts in kinin B1 receptor knockout mice. J. Clin. Periodontol., 2013, 40:653-660

[191] Hoshino A et al. Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts. J. Biol. Chem., 2010, 285:28826-28837

[192] Taddei SR et al. The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. Bone, 2013, 52:259-267

[193] Doucet M et al. CCL20/CCR6 signaling regulates bone mass accrual in mice. J. Bone Miner. Res., 2016, 31:1381-1390

[194] Zhao Huashan, Yan Dewen, Xiang Liang, Huang Chen, Li Jian, Yu Xiangfang, Huang Binbin, Wang Baobei, Chen Jie, Xiao Tianxia, Ren Pei-Gen, Zhang Jian V.. Chemokine-like receptor 1 deficiency leads to lower bone mass in male mice. Cellular and Molecular Life Sciences, 2018, 76 2 355-367

[195] Zhu W, Liang G, Huang Z, Doty SB, Boskey AL. Conditional inactivation of the CXCR4 receptor in osteoprecursors reduces postnatal bone formation due to impaired osteoblast development. J. Biol. Chem., 2011, 286:26794-26805

[196] Li J et al. Investigation of bioeffects of G protein-coupled receptor 1 on bone turnover in male mice. J. Orthop. Transl., 2017, 10:42-51

[197] Brommage R et al. High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes. Bone Res., 2014, 2:14034

[198] Bohlooly YM et al. Osteoporosis in MCHR1-deficient mice. Biochem. Biophys. Res. Commun., 2004, 318:964-969

[199] Xing Z et al. Multiple roles for CCR2 during fracture healing. Dis. Model Mech., 2010, 3:451-458

[200] Kawakami Y et al. SDF-1/CXCR4 axis in Tie2-lineage cells including endothelial progenitor cells contributes to bone fracture healing. J. Bone Miner. Res., 2015, 30:95-105

[201] Jacobs JP et al. Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis Rheum., 2010, 62:1921-1932

[202] Murakoshi M et al. Discovery and pharmacological effects of a novel GPR142 antagonist. J. Recept. Signal. Transduct. Res., 2017, 37:290-296

[203] Mader TL et al. CCR2 elimination in mice results in larger and stronger tibial bones but bone loss is not attenuated following ovariectomy or muscle denervation. Calcif. Tissue Int., 2014, 95:457-466

[204] Takebe K, Rai MF, Schmidt EJ, Sandell LJ. The chemokine receptor CCR5 plays a role in post-traumatic cartilage loss in mice, but does not affect synovium and bone. Osteoarthritis Cartilage, 2015, 23:454-461

[205] Andrade I et al. CCR5 down-regulates osteoclast function in orthodontic tooth movement. J. Dent. Res., 2009, 88:1037-1041

[206] Sambamurthy N et al. Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. J. Orthop. Res., 2018, 36:864-875

[207] Soriano-Guillen L et al. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J. Clin. Endocrinol. Metab., 2005, 90:147-151

[208] Bertelloni S et al. Long-term outcome of male-limited gonadotropin-independent precocious puberty. Horm. Res., 1997, 48:235-239

[209] Shenker A et al. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature, 1993, 365:652-654

[210] Rendina D et al. FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur. J. Endocrinol., 2010, 163:165-172

[211] Ferlin A et al. Mutations in the insulin-like factor 3 receptor are associated with osteoporosis. J. Bone Miner. Res., 2008, 23:683-693

[212] Liu RD et al. The Glu727 allele of thyroid stimulating hormone receptor gene is associated with osteoporosis. N. Am. J. Med. Sci., 2012, 4:300-304

[213] Orozco G et al. HLA-DPB1-COL11A2 and three additional xMHC loci are independently associated with RA in a UK cohort. Genes Immun., 2011, 12:169-175

[214] Styrkarsdottir U et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature, 2013, 497:517-520

[215] Ferlin A et al. New roles for INSL3 in adults. Ann. NY Acad. Sci., 2009, 1160:215-218

[216] van der Deure WM et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study. Clin. Endocrinol., 2008, 68:175-181

[217] Gwinn MR, Sharma A, De Nardin E. Single nucleotide polymorphisms of the N-formyl peptide receptor in localized juvenile periodontitis. J. Periodontol., 1999, 70:1194-1201

[218] Sun P et al. Loss of Lgr4 inhibits differentiation, migration and apoptosis, and promotes proliferation in bone mesenchymal stem cells. J. Cell. Physiol., 2019, 234:10855-10867

[219] Zhu C et al. LGR4 acts as a key receptor for R-spondin 2 to promote osteogenesis through Wnt signaling pathway. Cell. Signal., 2016, 28:989-1000

[220] Whyte LS et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl Acad. Sci. USA, 2009, 106:16511-16516

[221] Krieger NS et al. Increased bone density in mice lacking the proton receptor OGR1. Kidney Int., 2016, 89:565-573

[222] Orriss IR et al. The P2Y(6) receptor stimulates bone resorption by osteoclasts. Endocrinology, 2011, 152:3706-3716

[223] Hikiji H et al. TDAG8 activation inhibits osteoclastic bone resorption. FASEB J., 2014, 28:871-879

[224] Baribault H et al. The G-protein-coupled receptor GPR103 regulates bone formation. Mol. Cell. Biol., 2006, 26:709-717

[225] Orriss I et al. Bone phenotypes of P2 receptor knockout mice. Front. Biosci. (Sch. Ed.), 2011, 3:1038-1046

[226] Su X et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J. Clin. Invest., 2012, 122:3579-3592

[227] Francis N et al. Keratinocyte-specific ablation of protease-activated receptor 2 prevents gingival inflammation and bone loss in a mouse model of periodontal disease. Cell Microbiol., 2018, 20

[228] Hoebertz A, Meghji S, Burnstock G, Arnett TR. Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells. FASEB J., 2001, 15:1139-1148

[229] Wang N, Robaye B, Gossiel F, Boeynaems JM, Gartland A. The P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development. FASEB J., 2014, 28:2249-2259

[230] Ferrell WR et al. Essential role for proteinase-activated receptor-2 in arthritis. J. Clin. Invest., 2003, 111:35-41

[231] Wang N et al. Reduced bone turnover in mice lacking the P2Y13 receptor of ADP. Mol. Endocrinol., 2012, 26:142-152

[232] Orriss IR et al. Activation of the P2Y2 receptor regulates bone cell function by enhancing ATP release. J. Endocrinol., 2017, 233:341-356

[233] Xing Y et al. The roles of P2Y2 purinergic receptors in osteoblasts and mechanotransduction. PLoS ONE, 2014, 9

[234] Ke HZ et al. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol. Endocrinol., 2003, 17:1356-1367

[235] Gartland A et al. Multinucleated osteoclast formation in vivo and in vitro by P2X7 receptor-deficient mice. Crit. Rev. Eukaryot. Gene Expr., 2003, 13:243-253

[236] Bjarnadottir TK et al. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. Genomics, 2004, 84:23-33

[237] Harmar AJ. Family-B G-protein-coupled receptors. Genome Biol., 2001, 2

[238] Kwakkenbos MJ et al. The EGF-TM7 family: a postgenomic view. Immunogenetics, 2004, 55:655-666

[239] Stacey M, Lin HH, Gordon S, McKnight AJ. LNB-TM7, a group of seven-transmembrane proteins related to family-B G-protein-coupled receptors. Trends Biochem. Sci., 2000, 25:284-289

[240] Hamann J et al. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharmacol. Rev., 2015, 67:338-367

[241] Bjarnadottir TK, Fredriksson R, Schioth HB. The adhesion GPCRs: a unique family of G protein-coupled receptors with important roles in both central and peripheral tissues. Cell. Mol. Life Sci., 2007, 64:2104-2119

[242] Krasnoperov VG et al. alpha-latrotoxin stimulates exocytosis by the interaction with a neuronal G-protein-coupled receptor. Neuron, 1997, 18:925-937

[243] Lin HH et al. Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif. J. Biol. Chem., 2004, 279:31823-31832

[244] Arac D et al. A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. EMBO J., 2012, 31:1364-1378

[245] Promel S, Langenhan T, Arac D. Matching structure with function: the GAIN domain of adhesion-GPCR and PKD1-like proteins. Trends Pharmacol. Sci., 2013, 34:470-478

[246] Langenhan T et al. Latrophilin signaling links anterior-posterior tissue polarity and oriented cell divisions in the C. elegans embryo. Dev. Cell, 2009, 17:494-504

[247] Langenhan T, Aust G, Hamann J. Sticky signaling—adhesion class G protein-coupled receptors take the stage. Sci. Signal., 2013, 6:re3

[248] Ikegawa, S. Genomic study of adolescent idiopathic scoliosis in Japan. Scoliosis Spinal Dis. 11, 5 (2016).

[249] Kim JJ et al. Exome sequencing and subsequent association studies identify five amino acid-altering variants influencing human height. Hum. Genet., 2012, 131:471-478

[250] Qin XD et al. Genetic variant of GPR126 gene is functionally associated with adolescent idiopathic scoliosis in Chinese Population. Spine, 2017, 42:E1098-E1103

[251] Giampietro, P. F. SNPping away at the genetic basis of adolescent idiopathic scoliosis. Ann. Transl. Med. 3(Suppl. 1), 1–4 (2015).

[252] Xu JF et al. Association of GPR126 gene polymorphism with adolescent idiopathic scoliosis in Chinese populations. Genomics, 2015, 105:101-107

[253] Kou I et al. Genetic variants in GPR126 are associated with adolescent idiopathic scoliosis. Nat. Genet., 2013, 45:676-679

[254] Karnik SS et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol. Rev., 2015, 67:754-819

[255] Liebscher I, Schoneberg T, Promel S. Progress in demystification of adhesion G protein-coupled receptors. Biol. Chem., 2013, 394:937-950

[256] Liu JZ et al. Genome-wide association study of height and body mass index in Australian twin families. Twin Res. Hum. Genet., 2010, 13:179-193

[257] Soranzo N et al. Meta-analysis of genome-wide scans for human adult stature identifies novel Loci and associations with measures of skeletal frame size. PLoS Genet., 2009, 5

[258] Ravenscroft G et al. Mutations of GPR126 are responsible for severe arthrogryposis multiplex congenita. Am. J. Hum. Genet., 2015, 96:955-961

[259] Kitagaki J et al. A putative association of a single nucleotide polymorphism in GPR126 with aggressive periodontitis in a Japanese population. PLoS ONE, 2016, 11

[260] Tseng WY et al. High levels of soluble GPR56/ADGRG1 are associated with positive rheumatoid factor and elevated tumor necrosis factor in patients with rheumatoid arthritis. J. Microbiol. Immunol. Infect., 2018, 51:485-491

[261] Chen ZG, Gao PJ, Li ZP. Expression of G protein-coupled receptor 56 is an unfavorable prognostic factor in osteosarcoma patients. Tohoku J. Exp. Med., 2016, 239:203-211

[262] Liu ZQ, Zhang GR, Zhao CL, Li JM. Clinical significance of G protein-coupled receptor 110 (GPR110) as a novel prognostic biomarker in osteosarcoma. Med. Sci. Monit., 2018, 24:5216-5224

[263] Tonjes A et al. Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs. Hum. Mol. Genet., 2009, 18:4662-4668

[264] Kim YK et al. Gene-based copy number variation study reveals a microdeletion at 12q24 that influences height in the Korean population. Genomics, 2013, 101:134-138

[265] Karner CM, Long F, Solnica-Krezel L, Monk KR, Gray RS. Gpr126/Adgrg6 deletion in cartilage models idiopathic scoliosis and pectus excavatum in mice. Hum. Mol. Genet., 2015, 24:4365-4373

[266] Yeon Won H, Hwan Mun S, Shin B, Lee SK. Contradictory role of CD97 in basal and tumor necrosis factor-induced osteoclastogenesis in vivo. Arthritis Rheum., 2016, 68:1301-1313

[267] Hoek RM et al. Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis Rheum., 2010, 62:1036-1042

[268] Bjarnadottir TK et al. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics, 2006, 88:263-273

[269] Nordstrom KJ, Fredriksson R, Schioth HB. The amphioxus (Branchiostoma floridae) genome contains a highly diversified set of G protein-coupled receptors. BMC Evol. Biol., 2008, 8:9

[270] Lagerstrom MC et al. The G protein-coupled receptor subset of the chicken genome. PLoS Comput. Biol., 2006, 2

[271] Katanaev VL. The Wnt/Frizzled GPCR signaling pathway. Biochemistry (Mosc.), 2010, 75:1428-1434

[272] Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol., 2004, 20:781-810

[273] Wang Y, Chang H, Rattner A, Nathans J. Frizzled receptors in development and disease. Curr. Top. Dev. Biol., 2016, 117:113-139

[274] Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov., 2008, 7:339-357

[275] Kamesh N, Aradhyam GK, Manoj N. The repertoire of G protein-coupled receptors in the sea squirt Ciona intestinalis. BMC Evol. Biol., 2008, 8:129

[276] Huang HC, Klein PS. The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol., 2004, 5

[277] Vinson CR, Conover S, Adler PN. A Drosophila tissue polarity locus encodes a protein containing seven potential transmembrane domains. Nature, 1989, 338:263-264

[278] Kuhn C, Bufe B, Batram C, Meyerhof W. Oligomerization of TAS2R bitter taste receptors. Chem. Senses, 2010, 35:395-406

[279] Sugawara T et al. Diversification of bitter taste receptor gene family in western chimpanzees. Mol. Biol. Evol., 2011, 28:921-931

[280] Wang XX, Thomas SD, Zhang JZ. Relaxation of selective constraint and loss of function in the evolution of human bitter taste receptor genes. Hum. Mol. Genet., 2004, 13:2671-2678

[281] Kim U, Wooding S, Ricci D, Jorde LB, Drayna D. Worldwide haplotype diversity and coding sequence variation at human bitter taste receptor loci. Hum. Mutat., 2005, 26:199-204

[282] Zhang Y et al. Functional and association analysis of frizzled 1 (FZD1) promoter haplotypes with femoral neck geometry. Bone, 2010, 46:1131-1137

[283] Yerges LM et al. Functional characterization of genetic variation in the Frizzled 1 (FZD1) promoter and association with bone phenotypes: more to the LRP5 story? J. Bone Miner. Res., 2009, 24:87-96

[284] Frojmark AS et al. Mutations in Frizzled 6 cause isolated autosomal-recessive nail dysplasia. Am. J. Hum. Genet., 2011, 88:852-860

[285] Wilson NJ et al. Recessive mutations in the gene encoding frizzled 6 cause twenty nail dystrophy-expanding the differential diagnosis for pachyonychia congenita. J. Dermatol. Sci., 2013, 70:58-60

[286] Naz G et al. FZD6 encoding the Wnt receptor frizzled 6 is mutated in autosomal-recessive nail dysplasia. Br. J. Dermatol, 2012, 166:1088-1094

[287] Francke U. Williams-Beuren syndrome: genes and mechanisms. Hum. Mol. Genet., 1999, 8:1947-1954

[288] Albers J et al. Control of bone formation by the serpentine receptor Frizzled-9. J. Cell Biol., 2011, 192:1057-1072

[289] Heilmann A et al. The Wnt serpentine receptor Frizzled-9 regulates new bone formation in fracture healing. PLoS ONE, 2013, 8:12

[290] Wang Q, Huang C, Zeng F, Xue M, Zhang X. Activation of the Hh pathway in periosteum-derived mesenchymal stem cells induces bone formation in vivo: implication for postnatal bone repair. Am. J. Pathol., 2010, 177:3100-3111

[291] Di Paolo E et al. Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality. Peptides, 1999, 20:1187-1193

[292] Segre GV, Goldring SR. Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol. Metab., 1993, 4:309-314

[293] Holtmann MH, Ganguli S, Hadac EM, Dolu V, Miller LJ. Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J. Biol. Chem., 1996, 271:14944-14949

[294] Dong M, Wang Y, Pinon DI, Hadac EM, Miller LJ. Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling. J. Biol. Chem., 1999, 274:903-909

[295] Gourlet P et al. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor. Eur. J. Biochem., 1996, 239:349-355

[296] Vilardaga JP et al. Mutational analysis of extracellular cysteine residues of rat secretin receptor shows that disulfide bridges are essential for receptor function. Eur. J. Biochem., 1997, 246:173-180

[297] Dong M, Gao F, Pinon DI, Miller LJ. Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol. Endocrinol., 2008, 22:1489-1499

[298] Furness SG, Wootten D, Christopoulos A, Sexton PM. Consequences of splice variation on Secretin family G protein-coupled receptor function. Br. J. Pharmacol., 2012, 166:98-109

[299] Zupan, J., Komadina, R. & Marc, J. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. J. Biomed. Sci. 19, 28 (2012).

[300] Zmuda JM et al. Genetic analysis of vertebral trabecular bone density and cross-sectional area in older men. Osteoporos. Int., 2011, 22:1079-1090

[301] Lee HJ et al. Fracture, bone mineral density, and the effects of calcitonin receptor gene in postmenopausal Koreans. Osteoporos. Int., 2010, 21:1351-1360

[302] Masi L et al. Polymorphisms of the calcitonin receptor gene are associated with bone mineral density in postmenopausal Italian women. Biochem. Biophys. Res. Commun., 1998, 248:190-195

[303] Zofkova I, Zajickova K, Hill M, Krepelova A. Does polymorphism C1377T of the calcitonin receptor gene determine bone mineral density in postmenopausal women? Exp. Clin. Endocrinol. Diabetes, 2003, 111:447-449

[304] Kang BY, Kim JY, Lee KO. Association between an AluI polymorphism in the calcitonin receptor gene and quantitative ultrasound parameters in Korean men. Med. Princ. Pract., 2007, 16:389-393

[305] Tsai FJ, Chen WC, Chen HY, Tsai CH. The ALUI calcitonin receptor gene polymorphism (TT) is associated with low bone mineral density and susceptibility to osteoporosis in postmenopausal women. Gynecol. Obstet. Invest., 2003, 55:82-87

[306] Taboulet J et al. Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. Hum. Mol. Genet., 1998, 7:2129-2133

[307] Dacquin R et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J. Cell Biol., 2004, 164:509-514

[308] Rivadeneira F et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet., 2009, 41:1199-1206

[309] Aguiar-Oliveira MH et al. Older individuals heterozygous for a growth hormone-releasing hormone receptor gene mutation are shorter than normal subjects. J. Hum. Genet., 2015, 60:335-338

[310] Camats N et al. Contribution of human growth hormone-releasing hormone receptor (GHRHR) gene sequence variation to isolated severe growth hormone deficiency (ISGHD) and normal adult height. Clin. Endocrinol. (Oxf.), 2012, 77:564-574

[311] Inoue H et al. Identification and functional analysis of novel human growth hormone-releasing hormone receptor (GHRHR) gene mutations in Japanese subjects with short stature. Clin. Endocrinol., 2011, 74:223-233

[312] Martari M, Salvatori R. Diseases associated with growth hormone-releasing hormone receptor (GHRHR) mutations. Prog. Mol. Biol. Transl. Sci., 2009, 88:57-84

[313] Wang Q et al. Identification of a novel splicing mutation in the growth hormone (GH)-releasing hormone receptor gene in a Chinese family with pituitary dwarfism. Mol. Cell. Endocrinol., 2009, 313:50-56

[314] Oliveira CRP et al. Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene. Clin. Endocrinol., 2008, 69:153-158

[315] Salvatori R et al. Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene. J. Clin. Endocr. Metab., 1999, 84:917-923

[316] Baumann, G. Mutations in the growth hormone releasing hormone receptor: a new form of dwarfism in humans. Growth Horm. IGF Res. 9(Suppl. B), 24–29; discussion 29–30 (1999).

[317] Baumann G, Maheshwari H. The Dwarfs of Sindh: severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. Acta Paediatr., 1997, 86:33-38

[318] Wajnrajch MP, Gertner JM, Harbison MD, Chua SC, Leibel RL. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat. Genet., 1996, 12:88-90

[319] Harsloef, T. et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide-receptor (GIPR) gene is associated with bone mineral density, bone loss, and osteoporotic fractures: The Danish Osteoporosis Prevention Study. J. Bone Miner. Res. 28 (Suppl. 1), 138–139 (2013).

[320] Torekov SS et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J. Clin. Endocr. Metab., 2014, 99:E729-E733

[321] Scillitani A, Jang C, Wong BYL, Hendy GN, Cole DEC. A functional polymorphism in the PTHR1 promoter region is associated with adult height and BMD measured at the femoral neck in a large cohort of young caucasian women. Hum. Genet., 2006, 119:416-421

[322] Zhang YY et al. Tests of linkage and association of PTH/PTHrP receptor type 1 gene with bone mineral density and height in Caucasians. J. Bone Miner. Metab., 2006, 24:36-41

[323] Vilarino-Guell C et al. PTHR1 polymorphisms influence BMD variation through effects on the growing skeleton. Calcif. Tissue Int., 2007, 81:270-278

[324] Wynne F et al. Suggestive linkage of 2p22-25 and 11q12-13 with low bone mineral density at the lumbar spine in the Irish population. Calcif. Tissue Int., 2003, 72:651-658

[325] Schipani E, Provot S. PTHrP, PTH, and the PTH/PTHrP receptor in endochondral bone development. Birth. Defects Res. C Embryo. Today, 2003, 69:352-362

[326] Karaplis AC et al. Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. Endocrinology, 1998, 139:5255-5258

[327] Lanske B et al. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science, 1996, 273:663-666

[328] Hirai T et al. Bone is a major target of PTH/PTHrP receptor signaling in regulation of fetal blood calcium homeostasis. Endocrinology, 2015, 156:2774-2780

[329] Qiu T et al. PTH receptor signaling in osteoblasts regulates endochondral vascularization in maintenance of postnatal growth plate. J. Bone Miner. Res., 2015, 30:309-317

[330] Guo J, Chung U, Kondo H, Bringhurst FR, Kronenberg HM. The PTH/PTHrP receptor can delay chondrocyte hypertrophy in vivo without activating phospholipase C. Dev. Cell, 2002, 3:183-194

[331] Lanske B et al. The parathyroid hormone (PTH)/PTH-related peptide receptor mediates actions of both ligands in murine bone. Endocrinology, 1998, 139:5194-5204

[332] Karperien M et al. A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia. J. Clin. Endocrinol. Metab., 1999, 84:3713-3720

[333] Hopyan S et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat. Genet., 2002, 30:306-310

[334] Powell WF et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J. Endocrinol., 2011, 209:21-32

[335] Qiu T et al. IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition. Bone Res., 2018, 6:5

[336] Qiu T et al. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat. Cell Biol., 2010, 12:224-234

[337] Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr. Rev., 1993, 14:690-709

[338] Iwata A, Kanayama M, Oha F, Hashimoto T, Iwasaki N. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: a retrospective comparative study. BMC Musculoskelet. Disord., 2017, 18

[339] Lu R et al. Parathyroid hormone administration improves bone marrow microenvironment and partially rescues haematopoietic defects in Bmi1-null mice. PLoS ONE, 2014, 9

[340] Balani DH, Ono N, Kronenberg HM. Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J. Clin. Invest., 2017, 127:3327-3338

[341] Zheng L et al. Ciliary parathyroid hormone signaling activates transforming growth factor-beta to maintain intervertebral disc homeostasis during aging. Bone Res., 2018, 6:21

[342] Xie D et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone, 2005, 37:759-769

[343] Yamada C et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology, 2008, 149:574-579

[344] Tsukiyama K et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol. Endocrinol., 2006, 20:1644-1651

[345] Shen, W. R. et al. The glucagon-like peptide-1 receptor agonist exendin-4 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption via inhibition of TNF-alpha expression in macrophages. J. Immunol. Res. 2018, 5783639 (2018).

[346] Kerkhof HJ et al. A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum., 2010, 62:499-510

[347] Verleyen D, Luyten FP, Tylzanowski P. Orphan G-protein coupled receptor 22 (Gpr22) regulates cilia length and structure in the zebrafish Kupffer’s vesicle. PLoS ONE, 2014, 9

[348] Banziger C et al. Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell, 2006, 125:509-522

[349] Matsuda A et al. Large-scale identification and characterization of human genes that activate NF-kappa B and MAPK signaling pathways. Oncogene, 2003, 22:3307-3318

[350] Deng YH et al. The influence of the genetic and non-genetic factors on bone mineral density and osteoporotic fractures in Chinese women. Endocrine, 2013, 43:127-135

[351] Roshandel Delnaz, Thomson Wendy, Pye Stephen R., Boonen Steven, Borghs Herman, Vanderschueren Dirk, Huhtaniemi Ilpo T., Adams Judith E., Ward Kate A., Bartfai Gyorgy, Casanueva Felipe F., Finn Joseph D., Forti Gianni, Giwercman Aleksander, Han Thang S., Kula Krzysztof, Lean Michael E., Pendleton Neil, Punab Margus, Wu Frederick C., Holliday Kate L., O'Neill Terence W.. Polymorphisms in Genes Involved in the NF-κB Signalling Pathway Are Associated with Bone Mineral Density, Geometry and Turnover in Men. PLoS ONE, 2011, 6 11 e28031

[352] Styrkarsdottir Unnur, Halldorsson Bjarni V., Gudbjartsson Daniel F., Tang Nelson L. S., Koh Jung-Min, Xiao Su-mei, Kwok Timothy C. Y., Kim Ghi Su, Chan Juliana C. N., Cherny Stacey, Lee Seung Hun, Kwok Anthony, Ho Suzanne, Gretarsdottir Solveig, Pop Kostic Jelena, Palsson Stefan Th., Sigurdsson Gunnar, Sham Pak C., Kim Beom-Jun, Kung Annie W. C., Kim Shin-Yoon, Woo Jean, Leung Ping-C., Kong Augustine, Thorsteinsdottir Unnur, Stefansson Kari. European Bone Mineral Density Loci Are Also Associated with BMD in East-Asian Populations. PLoS ONE, 2010, 5 10 e13217

[353] Hsu YH et al. An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility Loci for osteoporosis-related traits. PLoS Genet., 2010, 6

[354] Zhong Z et al. Wntless functions in mature osteoblasts to regulate bone mass. Proc. Natl Acad. Sci. USA, 2012, 109:E2197-E2204

[355] Zhong ZA et al. Wntless spatially regulates bone development through beta-catenin-dependent and independent mechanisms. Dev. Dyn., 2015, 244:1347-1355

[356] Jovanovic M et al. Perturbed bone composition and integrity with disorganized osteoblast function in zinc receptor/Gpr39-deficient mice. FASEB J., 2018, 32:2507-2518

[357] Bologa CG et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol., 2006, 2:207-212

[358] Filardo EJ, Quinn JA, Frackelton AR Jr., Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol., 2002, 16:70-84

[359] Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem. Biophys. Res. Commun., 2006, 346:904-910

[360] Filardo E et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology, 2007, 148:3236-3245

[361] Revankar CM et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem. Biol., 2007, 2:536-544

[362] Heino TJ, Chagin AS, Savendahl L. The novel estrogen receptor G-protein-coupled receptor 30 is expressed in human bone. J. Endocrinol., 2008, 197:R1-R6

[363] Teplyuk NM et al. Runx2 regulates G protein-coupled signaling pathways to control growth of osteoblast progenitors. J. Biol. Chem., 2008, 283:27585-27597

[364] Martensson UE et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology, 2009, 150:687-698

[365] Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol., 2011, 11

[366] Popovics P, Stewart AJ. GPR39: a Zn(2+)-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions. Cell. Mol. Life Sci., 2011, 68:85-95

[367] Briscoe CP et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem., 2003, 278:11303-11311

[368] Itoh Y et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature, 2003, 422:173-176

[369] Kotarsky K, Nilsson NE, Olde B, Owman C. Improved reporter gene assays used to identify ligands acting on orphan seven-transmembrane receptors. Pharmacol. Toxicol., 2003, 93:249-258

[370] Latour MG et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes, 2007, 56:1087-1094

[371] Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun., 2003, 303:1047-1052

[372] Oh DY et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell, 2010, 142:687-698

[373] Cornish J et al. Modulation of osteoclastogenesis by fatty acids. Endocrinology, 2008, 149:5688-5695

[374] Mieczkowska A, Basle MF, Chappard D, Mabilleau G. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J. Biol. Chem., 2012, 287:23517-23526

[375] Monfoulet LE, Philippe C, Mercier S, Coxam V, Wittrant Y. Deficiency of G-protein coupled receptor 40, a lipid-activated receptor, heightens in vitro- and in vivo-induced murine osteoarthritis. Exp. Biol. Med. (Maywood), 2015, 240:854-866

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81722020, 91749204, 81472048)

Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission)(17JC1400903, 17411950300)